Clinical trials: Invasive Mold Disease
Invasive Fungal Disease
Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
This study is a post-approval commitment study, and is designed to further evaluate the safety and efficacy of isavuconazole in a relatively larger Chinese population who will receive isavuconazole treatment in a post-marketing…
- Trial name
- NCT05630976
- Testing
- Isavuconazole
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Pfizer
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Fungal Disease, Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium
Immunomonitoring of Mold Invasive Infections
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a…
- Trial name
- IMMUNOFIL (NCT06285188)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Aspergillosis, Invasive Fungal Infections
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal…
- Trial name
- VITAL (NCT00634049)
- Testing
- isavuconazole
- Where
- 96 sites in United States, Argentina and 17 more
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Inc
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark.
- Trial name
- NCT05774990
- Where
- Denmark
- Volunteers
- 621 people
- Sponsor
- University of Southern Denmark
Fungal Infection
CD5CAR-NK Cells for Refractory Invasive Mold Disease
CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD).
- Trial name
- CD5CAR-NK (NCT07454122)
- Testing
- CD5CAR-CBNK
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Mucormycosis; Pulmonary (Etiology)
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis.
- Trial name
- NCT05468372
- Testing
- Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Fusariosis, Onychomycosis
Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy…
- Trial name
- Fusarproph (NCT02714504)
- Testing
- Voriconazole or posaconazole
- Where
- Brazil
- Volunteers
- 239 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Invasive Fungal Infection
Registry of Patients Treated With Systemic Mold-Active Triazoles
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI).
- Trial name
- NCT03066011
- Testing
- Isavuconazonium sulfate, Voriconazole, Posaconazole
- Where
- 56 sites in United States
- Volunteers
- 2,015 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Invasive Mold Diseases
Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients
Invasive mold diseases (IMD) carry extremely high mortality rates in liver transplant recipients (aspergillosis prevalence ~1.8%, mortality 60%-90%; mucormycosis prevalence ~2%, mortality 38%-95%).
- Trial name
- NCT07725874
- Testing
- AmBisome (Amphotericin B) Liposome
- Volunteers
- 60 people
- Sponsor
- Beijing Friendship Hospital
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Mold Infections, Breakthrough Invasive Mold Infections
Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)
Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT).
- Conditions
- Invasive Mold Infections, Breakthrough Invasive Mold Infections, Hematologic Malignancy, Hematologic Diseases
- Trial name
- BIMI (NCT04720144)
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Invasive Mold Disease
A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD
Amphotericin B Cholesteryl Sulfate Complex (ABCD) is a generic drug of amphotericin B colloidal dispersion. This study aimed to explore the safety and efficacy of ABCD in patients with invasive mold disease.
- Trial name
- NCT07239765
- Testing
- ABCD
- Where
- China
- Volunteers
- 67 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Fungal Infection
A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing
This is a prospective, multicenter, randomized trial to study therapeutic drug monitoring (TDM) of voriconazole among patients with an invasive mould infection (IMI).
- Trial name
- VoriTDM (NCT01416025)
- Testing
- Prospective TDM Arm
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Aspergillosis, Invasive Fungal Infection
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
- Trial name
- NCT00412893
- Testing
- Isavuconazole, Voriconazole
- Where
- 107 sites in United States, Argentina and 24 more
- Volunteers
- 527 people
- Sponsor
- Astellas Pharma Inc
Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
- Trial name
- DOMINIC (NCT03827694)
- Testing
- Non-Invasive Testing for PIFI
- Where
- 33 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Arkansas Children's Hospital Research Institute